PDF herunterladen
Horm Metab Res 2022; 54(06): 380-388
DOI: 10.1055/a-1840-4374
Original Article: Endocrine Care

Differences in Clinical Aspects Between Subacute Thyroiditis Associated with COVID-19 Vaccines and Classical Subacute Thyroiditis

Ömercan Topaloğlu 
1   Endocrinology, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
2   Obesity and Diabetes Practice and Research Center, Zonguldak Bülent Ecevit University, Zonguldak, Turkey
,
Sakin Tekin
1   Endocrinology, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
,
Seda Nur Topaloğlu
3   Internal Medicine, Zonguldak Bulent Ecevit Universitesi Tip Fakultesi, Zonguldak, Turkey
,
Taner Bayraktaroglu
1   Endocrinology, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
2   Obesity and Diabetes Practice and Research Center, Zonguldak Bülent Ecevit University, Zonguldak, Turkey
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Subacute thyroiditis (SAT) developed after SARS-CoV-2 vaccines has been less studied. We aimed to compare classical SAT and SAT developed after SARS-CoV-2 vaccines in the context of clinical aspects. Adults with SAT detected in 90 days of COVID-19 vaccination (CoronaVac or Pfizer/BioNTech) were grouped as Vac-SAT. Those with a history of SARS-CoV-2 or upper respiratory tract infection in 6 months before the vaccination, or vaccination with another antiviral vaccine after COVID-19 vaccination were excluded. Those with SAT detected before COVID-19 pandemic were grouped as Classical-SAT. Of total (n=85), female/male (54/31) ratio and age [43 (23–65)] were similar in Vac-SAT (n=23) and Classical-SAT (n=62). Duration between vaccine and SAT was 45 (7–90) days, and similar in CoronaVac-SAT (n=5) and BioNTech-SAT (n=18). SAT-duration was 28 (10–150) days, and higher in Vac-SAT than in Classical-SAT (p=0.023). SAT was developed after the 1st dose vaccine in minority in CoronaVac-SAT (n=2) and BioNTech-SAT (n=3) (p=0.263). Previous LT4 use, and TSH elevation after resolution were more frequent in Vac-SAT than in Classical-SAT (p=0.027 and p=0.041). We included a considerable number of patients with SAT occurred after COVID-19 vaccines. We cannot provide clear evidence regarding the association of COVID-19 vaccines with SAT. SAT associated with CoronaVac or BioNTech seems unlikely to be occurred after the 1st dose, and to have a longer duration, more likely to be associated with previous LT4 use and lead TSH elevation after resolution than Classical-SAT. TSH should be followed-up after the resolution of SAT detected after COVID-19 vaccination.

Key words

subacute thyroiditis - vaccine - thyroiditis - COVID-19 - COVID-19 vaccine - SARS-CoV-2


Publikationsverlauf

Eingereicht: 14. April 2022

Angenommen nach Revision: 01. Mai 2022

Accepted Manuscript online:
01. Mai 2022

Artikel online veröffentlicht:
13. Juni 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 World Health Organization. WHO Coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int/table accessed 2022 February 7
  • 2 Haymana C, Demirci I, Tasci I. et al. Clinical outcomes of non-diabetic COVID-19 patients with different blood glucose levels: a nationwide Turkish study (TurCoGlycemia). Endocrine 2021; 73: 261-269
    CrossrefPubMedGoogle Scholar
  • 3 Sonmez A, Demirci I, Haymana C. et al. Clinical characteristics and outcomes of COVID-19 in patients with type 2 diabetes in Turkey: A nationwide study (TurCoviDia). J Diabetes 2021; 13: 585-595
    CrossrefPubMedGoogle Scholar
  • 4 Sahin I, Haymana C, Demir T. et al. Clinical characteristics and outcomes of COVID-19 patients with overweight and obesity: Turkish nationwide cohort study (TurCObesity). Exp Clin Endocrinol Diabetes 2022; 130: 115-124
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 5 Kazakou P, Paschou SA, Psaltopoulou T. et al. Early and late endocrine complications of COVID-19. Endocr Connect 2021; 10: R229-R239
    Google Scholar
  • 6 Mung SM, Jude EB. Interplay between endocrinology, metabolism and COVID-19 infection. Clin Med (Lond) 2021; 21: e499-e504
    Google Scholar
  • 7 Feghali K, Atallah J, Norman C. Manifestations of thyroid disease post COVID-19 illness: report of Hashimoto thyroiditis, Graves’ disease, and subacute thyroiditis. J Clin Transl Endocrinol Case Rep 2021; 22: 100094
    PubMedGoogle Scholar
  • 8 Pişkinpaşa H, Turgut S, Karaarslan Ö. et al. Disease activity is associated with depression and anxiety in Cushing’s syndrome during COVID-19 pandemic. Turk J Endocrinol Metab 2021; 25: 166-173
    CrossrefPubMedGoogle Scholar
  • 9 Lania A, Sandri MT, Cellini M. et al. Thyrotoxicosis in patients with COVID-19: the THYRCOV study. Eur J Endocrinol 2020; 183: 381-387
    Google Scholar
  • 10 Ünübol M, Erdemir Z, Çolak G. et al. Subacute thyroiditis associated with COVID-19 infection: two case reports. Turk J Endocrinol Metab 2021; 25: 344-348
    CrossrefPubMedGoogle Scholar
  • 11 Lazarus JH. Silent thyroiditis and subacute thyroiditis. In: Braverman LE, Utiger RD, (eds). The Thyroid: A Fundamental and Clinical Text, 7th ed. Philadelphia: Lippincott Williams & Wilkins; 1996. 577.
    Google Scholar
  • 12 Girgis CM, Russo RR, Benson K. Subacute thyroiditis following the H1N1 vaccine. J Endocrinol Invest 2010; 33: 506
    CrossrefPubMedGoogle Scholar
  • 13 Altay FA, Guz G, Altay M. Subacute thyroiditis following seasonal influenza vaccination. Hum Vaccin Immunother 2016; 12: 1033-1034
    CrossrefPubMedGoogle Scholar
  • 14 Hsiao JY, Hsin SC, Hsieh MC. et al. Subacute thyroiditis following influenza vaccine (Vaxigrip) in a young female. Kaohsiung J Med Sci 2006; 22: 297-300
    CrossrefPubMedGoogle Scholar
  • 15 Hernan Martinez J, Corder E, Uzcategui M. et al. Subacute thyroiditis and dyserythropoesis after influenza vaccination suggesting immune dysregulation. Bol Asoc Med P R 2011; 103: 48-52
    PubMedGoogle Scholar
  • 16 Toft J, Larsen S, Toft H. Subacute thyroiditis after hepatitis B vaccination. Endocr J 1998; 45: 135
    PubMedGoogle Scholar
  • 17 Passah A, Arora S, Damle NA. et al. Occurrence of subacute thyroiditis following influenza vaccination. Indian J Endocrinol Metab 2018; 22: 713-714
    CrossrefPubMedGoogle Scholar
  • 18 https://covid19asi.saglik.gov.tr/?_Dil=2 accessed 2022 February 7
  • 19 Saygılı ES, Karakilic E. Subacute thyroiditis after inactive SARS-CoV-2 vaccine. BMJ Case Rep 2021; 14: e244711
    CrossrefPubMedGoogle Scholar
  • 20 Bostan H, Unsal IO, Kizilgul M. et al. Two cases of subacute thyroiditis after different types of SARS-CoV-2 vaccination. Arch Endocrinol Metab 2022; 66: 97-103
    CrossrefPubMedGoogle Scholar
  • 21 Topaloğlu Ö, Tekin S, Topaloğlu SN. et al. Persistent subacute thyroiditis post SARS-CoV-2 vaccine in a male patient with positive thyroid autoantibodies. Turk J Endocrinol Metab 2022; 26: 48-54
    CrossrefPubMedGoogle Scholar
  • 22 Sözen M, Topaloğlu Ö, Çetinarslan B. et al. COVID-19 mRNA vaccine may trigger subacute thyroiditis. Hum Vaccin Immunother 2021; 17: 5120-5125
    CrossrefPubMedGoogle Scholar
  • 23 Ippolito S, Gallo D, Rossini A. et al. SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review. J Endocrinol Invest 2022; 29: 1-12
    PubMedGoogle Scholar
  • 24 Bahçecioğlu AB, Karahan ZC, Aydoğan BI. et al. Subacute thyroiditis during the COVID-19 pandemic: a prospective study. J Endocrinol Invest 2022; 45: 865-874
    CrossrefPubMedGoogle Scholar
  • 25 Ross DS, Burch HB, Cooper DS. et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26: 1343-1421 Erratum: Thyroid 2017; 27: 1462
    CrossrefPubMedGoogle Scholar
  • 26 Park SY, Kim EK, Kim MJ. et al. Ultrasonographic characteristics of subacute granulomatous thyroiditis. Korean J Radiol 2006; 7: 229-234
    CrossrefPubMedGoogle Scholar
  • 27 Burman KD. https://www.uptodate.com/contents/subacute-thyroiditis?search=subacute%20thyroiditis&source=search_result&selectedTitle=1~42&usage_type=default&display_rank=1 accessed 2022 February 7
  • 28 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-280.e8
    Google Scholar
  • 29 Rotondi M, Coperchini F, Ricci G. et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest 2021; 44: 1085-1090
    CrossrefPubMedGoogle Scholar
  • 30 Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol 2021; 11: 617089
    CrossrefPubMedGoogle Scholar
  • 31 Oğuz SH, Şendur SN, İremli BG. et al. SARS-CoV-2 vaccine-induced thyroiditis: safety of re-vaccinations and clinical follow-up. J Clin Endocrinol Metab 2022; 107: e1823-e1834
    CrossrefPubMedGoogle Scholar
  • 32 Sencar ME, Calapkulu M, Sakiz D. et al. An evaluation of the results of the steroid and non-steroidal anti-inflammatory drug treatments in subacute thyroiditis in relation to persistent hypothyroidism and recurrence. Sci Rep 2019; 9: 16899
    CrossrefPubMedGoogle Scholar
  • 33 Sencar ME, Çalapkulu M, Sakız D. et al. Frequency of thyroid antibodies at the diagnosis of subacute thyroiditis. Turk J Endocrinol Metab 2020; 24: 144-148
    CrossrefPubMedGoogle Scholar
  • 34 Cengiz H, Varim C, Demirci T. et al. Hemogram parameters in the patients with subacute thyroiditis. Pak J Med Sci 2020; 36: 240-245
    PubMedGoogle Scholar
  • 35 Das L, Bhadada SK, Sood A. Post-COVID-vaccine autoimmune/inflammatory syndrome in response to adjuvants (ASIA syndrome) manifesting as subacute thyroiditis. J Endocrinol Invest 2022; 45: 465-467
    CrossrefPubMedGoogle Scholar
  • 36 Vasileiou V, Paschou SA, Tzamali X. et al. Recurring subacute thyroiditis after SARS-CoV-2 mRNA vaccine: A case report. Case Rep Womens Health 2022; 33: e00378
    CrossrefPubMedGoogle Scholar